ArticleBMC cancer2023

A non-inferiority randomized phase III trial of standard immunotherapy by checkpoint inhibitors vs. reduced dose intensity in responding patients with metastatic cancer: the MOIO protocol study.

Gwenaelle Gravis et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.